New Johnson & Johnson data show high booster shot effectiveness
Data from a phase III trial demonstrate a 94-percent protection against Covid-19 with a Johnson & Johnson booster shot.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
An additional dose of Johnson & Johnson's Covid-19 vaccine has shown an effectiveness of 94 percent, the company just announced in the published results of a phase III trial.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA begins assessment of Pfizer booster application
For subscribers
Denmark sells 500,000 surplus vaccines to New Zealand
For subscribers
Danish government cancels vaccine production tender
For subscribers
